| Product |
Drug Class |
Therapeutic Action |
Indication |
Stage |
EPI-12323
Asthma |
Steroid replacement Small molecule |
Anti inflammation, bronchodilation, decreases neutrophils |
Asthma (aerosol administration) |
Phase II |
EPI-12323
COPD |
Steroid replacement
Small molecule |
Anti inflammation, bronchodilation, decreases neutrophils |
COPD (aerosol administration) |
Phase II |
EPI-12323
Allergic Rhinitis |
Steroid replacement
Small molecule |
Anti inflammatory |
Allergic Rhinitis |
Phase I |
| EPI-12323 Combinations |
Steroid replacement
Small molecule |
Anti-inflammatory |
Asthma, COPD |
Phase I |
This compound has been shown to be effective in reducing airway inflammation, improving airways resistance and compliance and reducing hyper responsiveness in three separate preclinical models of human asthma. Phase IIa has been completed using allergen challenge as the model, and the compound has been shown to be safe and effective. Check back soon for updates on Phase II clinical study results in mild-moderate asthma patients in three dose groups. Epigenesis is continuing its product development efforts by observing a broader asthma population in a Phase II clinical study using its new formulation in an advanced high-efficiency nebulizer device. Epigenesis expects to complete its Phase II clinical study in a broader asthma population in 2007.
As a result of its ability to decrease both eosinophilic and neutrophilic inflammation in the lungs, EPI-12323 is also being developed for COPD. Check back soon for updates on Phase II clinical study results in moderate-severe COPD patients in three dose groups.
Over 250 patients have now been safely dosed with EPI-12323.
Epigenesis has completed preclinical pharmacology studies combining EPI-12323 with a long acting beta agonist.
|
